| 发明名称 |
COMBINATIONS OF THERAPEUTIC AGENTS FOR TREATING CANCER |
| 摘要 |
The invention relates to a combination comprising the N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)-ethyl]-amino]methyl]phenyl]-2E-2-propenamide; and one or more pharmaceutically active agents; pharmaceutical compositions comprising said combination; methods of treatment comprising said combination; processes for making said combination; and a commercial package comprising said combination. |
| 申请公布号 |
US2017027909(A1) |
申请公布日期 |
2017.02.02 |
| 申请号 |
US201615222370 |
申请日期 |
2016.07.28 |
| 申请人 |
Novartis AG |
发明人 |
Atadja Peter Wisdom;Shao Wenlin;Bhalla Kapil N. |
| 分类号 |
A61K31/404;A61K31/548;A61K38/05;A61K31/704 |
主分类号 |
A61K31/404 |
| 代理机构 |
|
代理人 |
|
| 主权项 |
1. A combination of:
(a) N-hydroxy-3-[4-[[[2-(2-methyl-1H-indol-3-yl)-ethyl]-amino]methyl]phenyl]-2E-2-propenamide or a pharmaceutically acceptable salt thereof; and (b) a proteosome inhibitor, wherein the proteasome inhibitor is selected from the group consisting of aclacinomycin A; gliotoxin; PS-341; MLN 34 and bortezomib or a pharmaceutically acceptable salt thereof or a topoisomerase inhibitor, wherein the topoisomerase inhibitor is selected from the group consisting of idarubicin, doxorubicin; epirubicirn, and mitoxantrone or a pharmaceutically acceptable salt thereof. |
| 地址 |
Basel CH |
